Back
Immunovant, Inc. (IMVT)
BiotechnologyIMVT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$43.51
+0.44%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-2.77
ROE
-64.8%
Gross margin
0.0%
Debt/Equity
0.01x
Revenue growth
P/B ratio
Beta
Forward P/E
Immunovant, Inc. — company intelligence
Earnings surprises
Q1 2027$-0.75 vs $-0.63 est-19.5%
Q4 2026$-0.73 vs $-0.61 est-19.1%
Q3 2026$-0.61 vs $-0.73 est+16.3%
Q2 2026$-0.73 vs $-0.73 est+0.2%
Analyst consensus · 22 analysts
18 Buy4 Hold0 Sell
Updated Aug 13, 2026
Insider activity · 90 days
0 buys21 sellsnet -406,228 shares
Pande Atulother 1,500 · Jul 24, 2026
Girao TiagoSell 6,798 · Jul 23, 2026
Stout Jay SSell 2,857 · Jul 23, 2026
Recent SEC filings
4 — Insider transaction reportAug 21, 2026
8-K — Material event reportAug 6, 2026
10-Q — Quarterly reportAug 6, 2026
Latest news
Immunovant (IMVT) Q1 2027 Earnings Call Transcript — Yahoo · 1w ago
Roivant Sciences Q1 Earnings Call Highlights — Yahoo · 2w ago
Immunovant, Inc. Q1 2027 Earnings Call Summary — Yahoo · 2w ago
Immunovant Q1 Earnings Call Highlights — Yahoo · 2w ago
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript — SeekingAlpha · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.